FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W977024581> ?p ?o ?g. }

• W977024581 endingPage "5743" @default.
• W977024581 startingPage "5743" @default.
• W977024581 abstract "Abstract Introduction: Bortezomib (Velcade¨; V), a proteasome inhibitor, is currently FDA (Food and Drug Administration) approved for the treatment of multiple myeloma (MM) and relapsed mantle cell lymphoma. Common side effects reported with its use include thrombocytopenia, fatigue, peripheral neuropathy and neutropenia. Ocular complications associated with bortezomib are less well described. We describe 6 patients with multiple myeloma who developed meibomitis, multiple chalazions and blepharitis after treatment with bortezomib containing regimens, resulting in delay and in some cases termination of the therapy. Methods: We reviewed the charts of forty patients who received induction chemotherapy for multiple myeloma between June 2013-June 2014 at Montefiore Medical Center, New York. Charts were reviewed for data pertaining to demographics, chemotherapy regimen and schedule as well as follow up of ocular symptoms. Results: Six of these forty (15%) patients complained about bilateral eye soreness, itching and redness. They did not have any evidence of viral or upper respiratory infections. Ophthalmology evaluation showed blepharitis, meibomitis and multiple chalazion. Majority of the patients were 60 years or greater, with 50% African-Americans. Half of the cases had stage 3 MM with a median duration of chemotherapy 8 weeks prior to onset of ocular symptoms. 4 of these 6 patients received VCD regimen (Bortezomib via subcutaneous route and Cyclophosphamide/ Dexamethasone as tablets) while the remaining 2 patients received VD and VCD-R (addition of Lenalidomide) via intravenous and subcutaneous route respectively. Ocular symptoms led to a 1-3 week delay in the next cycle of chemotherapy. These symptoms promptly responded to withdrawal of chemotherapy and other conservative measures. Chemotherapy was resumed in 4 out of 6 patients, with recurrence of chalazion in two patients within 3 weeks of starting Bortezomib. Conclusions: Ocular symptoms are commonly seen but rarely reported with bortezomib therapy. They can adversely affect patient's quality of life as well as lead to interruption in chemotherapy. Although these symptoms respond well to withdrawal of chemotherapy and conservative measures, the rate of recurrence is high once bortezomib is resumed. Awareness of these complications and early intervention can potentially avoid treatment delay. Figure 1 Figure 1. Figure 2 Figure 2. Disclosures No relevant conflicts of interest to declare." @default.
• W977024581 created "2016-06-24" @default.
• W977024581 creator A5024200471 @default.
• W977024581 creator A5055212021 @default.
• W977024581 creator A5059588535 @default.
• W977024581 creator A5061052702 @default.
• W977024581 creator A5068938453 @default.
• W977024581 creator A5069943558 @default.
• W977024581 creator A5090050508 @default.
• W977024581 date "2014-12-06" @default.
• W977024581 modified "2023-10-14" @default.
• W977024581 title "Ocular Complications of Bortezomib Therapy in Multiple Myeloma" @default.
• W977024581 doi "https://doi.org/10.1182/blood.v124.21.5743.5743" @default.
• W977024581 hasPublicationYear "2014" @default.
• W977024581 type Work @default.
• W977024581 sameAs 977024581 @default.
• W977024581 citedByCount "1" @default.
• W977024581 countsByYear W9770245812022 @default.
• W977024581 crossrefType "journal-article" @default.
• W977024581 hasAuthorship W977024581A5024200471 @default.
• W977024581 hasAuthorship W977024581A5055212021 @default.
• W977024581 hasAuthorship W977024581A5059588535 @default.
• W977024581 hasAuthorship W977024581A5061052702 @default.
• W977024581 hasAuthorship W977024581A5068938453 @default.
• W977024581 hasAuthorship W977024581A5069943558 @default.
• W977024581 hasAuthorship W977024581A5090050508 @default.
• W977024581 hasConcept C126322002 @default.
• W977024581 hasConcept C141071460 @default.
• W977024581 hasConcept C2776364478 @default.
• W977024581 hasConcept C2776694085 @default.
• W977024581 hasConcept C2777063308 @default.
• W977024581 hasConcept C2777478702 @default.
• W977024581 hasConcept C2780401358 @default.
• W977024581 hasConcept C2781413609 @default.
• W977024581 hasConcept C71924100 @default.
• W977024581 hasConceptScore W977024581C126322002 @default.
• W977024581 hasConceptScore W977024581C141071460 @default.
• W977024581 hasConceptScore W977024581C2776364478 @default.
• W977024581 hasConceptScore W977024581C2776694085 @default.
• W977024581 hasConceptScore W977024581C2777063308 @default.
• W977024581 hasConceptScore W977024581C2777478702 @default.
• W977024581 hasConceptScore W977024581C2780401358 @default.
• W977024581 hasConceptScore W977024581C2781413609 @default.
• W977024581 hasConceptScore W977024581C71924100 @default.
• W977024581 hasIssue "21" @default.
• W977024581 hasLocation W9770245811 @default.
• W977024581 hasOpenAccess W977024581 @default.
• W977024581 hasPrimaryLocation W9770245811 @default.
• W977024581 hasRelatedWork W2112489854 @default.
• W977024581 hasRelatedWork W2165065963 @default.
• W977024581 hasRelatedWork W2366030768 @default.
• W977024581 hasRelatedWork W2427804748 @default.
• W977024581 hasRelatedWork W2583825766 @default.
• W977024581 hasRelatedWork W2934354596 @default.
• W977024581 hasRelatedWork W2980910443 @default.
• W977024581 hasRelatedWork W3134875278 @default.
• W977024581 hasRelatedWork W4241469660 @default.
• W977024581 hasRelatedWork W4313857557 @default.
• W977024581 hasVolume "124" @default.
• W977024581 isParatext "false" @default.
• W977024581 isRetracted "false" @default.
• W977024581 magId "977024581" @default.
• W977024581 workType "article" @default.